Scleroderma:The Anti-Scl 70 False Alarm

Discover the truth behind anti-Scl 70 antibodies in our latest video. These antibodies, often detected in scleroderma testing, can stir up concern due to their implications for skin and lung involvement, alongside prognosis. However, the accuracy of these tests may be compromised by false positives, leading to unnecessary anxiety and costly follow-up tests like HRCT scans and echocardiograms. Our video dives into why these antibodies, despite their importance, should be interpreted cautiously in light of clinical symptoms. Explore the science behind anti-Scl 70 antibodies, their role in cellular replication, and the challenges posed by current testing methods like ELISA and chemiluminescent immunoassay (CIA). Join us as we unravel the complexities of scleroderma diagnosis and the need for more reliable testing protocols.
For more information:
Systemic Scleroderma-Definition, Clinical Picture and
Laboratory Diagnostics - www.ncbi.nlm.n...
False positive anti-Topoisomerase I (Scl-70) antibody results
in clinical practice: A case series from a scleroderma referral
center- www.ncbi.nlm.n...
Classification Criteria for Systemic Sclerosis: An ACR-EULAR
Collaborative Initiative - www.ncbi.nlm.n...
The Effect of Anti-Scl-70 Antibody Determination Method
on Its Predictive Significance for Interstitial Lung Disease
Progression in Systemic Sclerosis - www.ncbi.nlm.n...